Stem Cell Transplant in Pediatric Leukemia Not Affected by Donor Type

Share this content:
High-risk pediatric patients with ALL see no difference in outcomes after HSCT based on donor type
High-risk pediatric patients with ALL see no difference in outcomes after HSCT based on donor type

High-risk pediatric patients with acute lymphoblastic leukemia (ALL) see no difference in outcomes after hematopoietic stem-cell transplantation (HSCT) based on donor type, according to a recent study published in the Journal of Clinical Oncology.

Christina Peters, MD, PhD, of St. Anna Children's Hospital in Vienna and fellow researchers looked at 411 children with high-risk ALL who received standardized HSCT during first or later remissions.

They acquired human leukocyte antigen (HLA)-matched grafts that were gathered from either genoidentical siblings or unrelated donors that were compatible.

RELATED: Inotuzumab Ozogamicin + MiniHCVD: New Standard of Care for Frontline Leukemia in Older Patients?

The researchers found no difference in event-free or overall survival as well as non-relapse mortality in the unrelated donor group as compared to the genoidentical group. Absence of chronic graft-versus-host disease did not affect event-free survival.

Engraftment was found to be faster in genoidentically-grafted patients after bone marrow transplantation and was associated with fewer severe infections and pulmonary complications.

“Outcome among high-risk pediatric patients with ALL after HSCT was not affected by donor type,” the authors concluded. “Standardized myeloablative conditioning produced a low incidence of treatment-related mortality and effective control of leukemia.”


  1. Peters, Christina, et al. "Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial." Journal of Clinical Oncology. doi: 10.1200/JCO.2014.58.9747. [epub ahead of print]. March 9, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs